Christopher Sarchi
Vermogen: 2 M $ op 31-05-2026
Vermogen: 2 M $ op 31-05-2026
Christopher Sarchi is currently Chief Commercial Officer at Bicara Therapeutics, Inc. since 2026 and Chief Commercial Officer at Replimune Group, Inc. since 2022.
Former positions include Director-Oncology Regional Sales at Genentech, Inc. from 2010 to 2013 and Head-Commercial Oncology US Region at Sanofi.
Education includes undergraduate studies at the University of Maine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-06-2026 | 180.962 ( 0,23% ) | 2 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BICARA THERAPEUTICS INC. | Corporate Officer/Principal | 08-05-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| REPLIMUNE GROUP, INC. | Corporate Officer/Principal | 01-05-2026 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01-01-2013 |
| SANOFI | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
University of Maine
University of Maine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau